About Us

Mark Iwicki

Mark Iwicki

Executive Chairman

Mr. Iwicki has 25 years of experience as a pharmaceutical industry leader across multiple therapeutic areas. He has extensive experience building businesses and has been instrumental in the success of a number of drugs, including Prilosec®, Diovan®, Zelnorm®, Lunesta®, and Latuda®. Prior to joining Kala, Mr. Iwicki was President and Chief Executive Officer of Civitas Therapeutics, which was acquired by Acorda Therapeutics.  Read More »


Charlie McDermott

Charlie McDermott

President and Chief Business Officer

Mr. McDermott has 20 years of operating experience in the biotechnology and ophthalmology industry. He most recently served as Vice President of Business Development, Eye Care and Drug Delivery at Allergan, an ophthalmic industry leader.  Read More »


Kim Brazzell, PhD

Kim Brazzell, PhD

Chief Medical Officer

Dr. Brazzell brings more than 25 years of experience in the ophthalmic pharmaceutical industry to Kala. Previously, he held several executive positions at Inspire Pharmaceuticals, including Executive Vice President of Medical and Scientific Affairs, Executive Vice President and Head of Ophthalmology Business, and Senior Vice President of Ophthalmic Research and Development.  Read More »


Hongming Chen, ScD

Hongming Chen, ScD

Chief Scientific Officer

Dr. Chen joined Kala from TransForm Pharmaceuticals, where she was Director of Formulation Development and was responsible for formulation design for drugs and drug/device combinations. Dr. Chen was the founding employee at TransForm, and helped to build the company to its acquisition by Johnson & Johnson in 2005 for $230 million.  Read More »


Mary Reumuth

Mary Reumuth

Vice President, Finance and Corporate Controller

Ms. Reumuth brings with her nearly 20 years of diversified finance and accounting experience. She was formerly Corporate Controller for Enobia Pharma (acquired by Alexion Pharmaceuticals).  Read More »